MY157716A - Solid dosage form of olmesartan medoxomil and amlodipine - Google Patents

Solid dosage form of olmesartan medoxomil and amlodipine

Info

Publication number: MY157716A
Authority: MY; Malaysia
Prior art keywords: solid dosage; dosage form; olmesartan medoxomil; amlodipine; acceptable salt
Prior art date: 2006-09-15

Application number

MYPI20091051A

Other languages

English (en)

Inventor

Bauer Wolfgang

Lichey Johann

Teubner Andreas

Wadenstorfer Elmar

Original Assignee

Daiichi Sankyo Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-15

Filing date

2007-10-12

Publication date

2016-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38754721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY157716(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-10-12 Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd

2016-07-15 Publication of MY157716A publication Critical patent/MY157716A/en

Links

239000007909 solid dosage form Substances 0.000 title abstract 4
229940043092 olmesartan medoxomil and amlodipine Drugs 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 2
239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 abstract 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 abstract 1
UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 abstract 1
229960002003 hydrochlorothiazide Drugs 0.000 abstract 1
229960001199 olmesartan medoxomil Drugs 0.000 abstract 1
150000008163 sugars Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

MYPI20091051A 2006-09-15 2007-10-12 Solid dosage form of olmesartan medoxomil and amlodipine MY157716A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US84509006P	2006-09-15	2006-09-15

Publications (1)

Publication Number	Publication Date
MY157716A true MY157716A (en)	2016-07-15

Family

ID=38754721

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MYPI20091051A MY157716A (en)	2006-09-15	2007-10-12	Solid dosage form of olmesartan medoxomil and amlodipine

Country Status (22)

Country	Link
US (2)	US20090175942A1 (de)
JP (1)	JP5344620B2 (de)
AT (1)	AT509493B1 (de)
AU (1)	AU2007297333B2 (de)
BR (1)	BRPI0716893A2 (de)
CH (1)	CH703897B1 (de)
DE (1)	DE212007000063U1 (de)
DK (1)	DK200900369A (de)
FI (1)	FI124122B (de)
GB (1)	GB2454620B (de)
IL (1)	IL197518A0 (de)
IS (1)	IS8808A (de)
MY (1)	MY157716A (de)
NZ (1)	NZ575422A (de)
PT (1)	PT2008032107W (de)
RU (1)	RU2423975C2 (de)
SE (1)	SE0900332L (de)
SK (1)	SK288460B6 (de)
TR (1)	TR200901984T1 (de)
TW (1)	TWI399223B (de)
WO (1)	WO2008032107A1 (de)
ZA (1)	ZA200810616B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2598449Y2 (ja)	1993-08-06	1999-08-09	株式会社ソミック石川	ボールジョイント
US20110038898A1 (en)	2008-03-13	2011-02-17	Shuichi Yada	Dissolution properties of drug products containing olmesartan medoxomil
TW201000097A (en) *	2008-05-30	2010-01-01	Daiichi Sankyo Co Ltd	Medicament for the prophylaxis or treament of hypertension
US20120115837A1 (en) *	2009-04-30	2012-05-10	Takeda Pharmaceutical Company Limited	Solid Preparation
CA2790817A1 (en) *	2010-02-24	2011-09-01	Sanofi-Aventis Deutschland Gmbh	Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
EP2425859A1 (de) *	2010-08-08	2012-03-07	Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi	Formulationen von Olmesartan
CN102028663B (zh) *	2010-12-14	2011-11-30	北京万生药业有限责任公司	一种稳定的奥美沙坦酯固体制剂
JP6018420B2 (ja) *	2012-06-05	2016-11-02	ニプロ株式会社	アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
CN103565807B (zh) *	2012-07-25	2015-11-04	天津市汉康医药生物技术有限公司	一种奥美沙坦酯氨氯地平药物组合物
TW201427720A (zh) *	2012-10-12	2014-07-16	Ajinomoto Kk	含有鈣拮抗劑及血管張力素ｉｉ受體拮抗劑之醫藥製劑之製造方法
JP5871984B2 (ja) *	2013-04-15	2016-03-01	株式会社三和化学研究所	オルメサルタンメドキソミルを含有する医薬組成物
JPWO2014188729A1 (ja) *	2013-05-24	2017-02-23	持田製薬株式会社	経口用組成物
EP2883539A1 (de)	2013-12-12	2015-06-17	Sanovel Ilac Sanayi ve Ticaret A.S.	Pharmazeutische Kombinationen aus Olmesartan und Amlodipin
CN104739799B (zh) *	2013-12-27	2018-01-05	辰欣药业股份有限公司	一种用于直接压片的苯磺酸氨氯地平组合物及其片剂制备方法
KR102222917B1 (ko) *	2014-06-25	2021-03-05	한림제약(주)	암로디핀 및 올메사탄 메독소밀을 포함하는 약학 조성물
CN109875972B (zh) *	2015-07-08	2021-08-03	南京正大天晴制药有限公司	一种奥美沙坦酯氨氯地平药物组合物
CN105902510A (zh) *	2015-12-24	2016-08-31	嘉实（湖南）医药科技有限公司	一种奥美沙坦酯氨氯地平复方制剂的制备工艺
US12303507B2 (en)	2019-02-26	2025-05-20	Daewoong Pharmaceutical Co., Ltd.	Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia
CN115300476B (zh) *	2022-09-01	2024-04-16	华润双鹤药业股份有限公司	一种药物组合物及其制备方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3025292A (en)		1962-03-13		Reduction of i
DK161312C (da)	1982-03-11	1991-12-09	Pfizer	Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en)	1986-04-04	1986-05-08	Pfizer Ltd	Pharmaceutically acceptable salts
US4772596A (en) *	1986-10-09	1988-09-20	Sankyo Company Limited	Dihydropyridine derivatives, their preparation and their use
US5270317A (en) *	1990-03-20	1993-12-14	Elf Sanofi	N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5260285A (en) *	1990-12-07	1993-11-09	Merck & Co., Inc.	Substituted imidazopyridazines as angiotensin II antagonists
US5250521A (en) *	1990-12-07	1993-10-05	Merck & Co., Inc.	Substituted pyrazolopyrimidines as angiotensin II antagonists
US5656650A (en) *	1990-12-14	1997-08-12	Smithkline Beecham Corp.	Angiotensin II receptor blocking compositions
US5616599A (en)	1991-02-21	1997-04-01	Sankyo Company, Limited	Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5238942A (en) *	1991-05-10	1993-08-24	Merck & Co., Inc.	Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US5492904A (en) *	1991-05-15	1996-02-20	E. I. Du Pont De Nemours And Company	Composition of angiotensin-II receptor antagonists and calcium channel blockers
JPH05967A (ja) *	1991-06-19	1993-01-08	Yamanouchi Pharmaceut Co Ltd	組織プラスミノーゲンアクチベーター含有製剤組成物
US5246944A (en) *	1991-08-13	1993-09-21	Merck & Co., Inc.	Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
FR2688781B1 (fr) *	1992-03-23	1994-07-01	Sanofi Elf	Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
US5312820A (en) *	1992-07-17	1994-05-17	Merck & Co., Inc.	Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5721263A (en) *	1993-06-07	1998-02-24	Takeda Chemical Industries, Ltd.	Pharmaceutical composition for angiotensin II-mediated diseases
GB9405833D0 (en) *	1994-03-24	1994-05-11	Pfizer Ltd	Separation of the enantiomers of amlodipine
US6036977A (en) *	1995-09-29	2000-03-14	L.A.M. Pharmaceutical Corp.	Drug preparations for treating sexual dysfunction
US5952006A (en) *	1995-09-29	1999-09-14	L.A.M. Pharmaceuticals, Llc	Drug preparations for treating impotency
US6251436B1 (en) *	1995-09-29	2001-06-26	L.A.M. Pharmaceutical Corporation	Drug preparations for treating sexual dysfunction
US5808084A (en) *	1996-02-14	1998-09-15	Pfizer, Inc.	Process for the preparation of 1,4-dihydropyridinedicarboxylic esters
EP0795327A1 (de) *	1996-03-13	1997-09-17	Pfizer Inc.	Verwendung von Amlodipin zur Behandlung von Prophylaxe von kongestivem Herzversagen nichtischämischen Ursprungs
US6420412B2 (en) *	1996-03-29	2002-07-16	Smithkline Beecham Corporation	Eprosartan dihydate and a process for its production and formulation
DE69731840T2 (de) *	1996-07-15	2005-08-04	Sankyo Co., Ltd.	Pharmazeutische Zusammensetzungen enthaltend CS-866 und Insulinresistenz verbessernde Mittel und deren Verwendung zur Behandlung von Arteriosklerose und Xanthom
US6262102B1 (en) *	1997-06-27	2001-07-17	Smithkline Beecham Corporation	Eprosartan monohydrate
US6630498B2 (en) *	1997-08-06	2003-10-07	Smithkline Beecham Corporation	Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
US20010044584A1 (en) *	1997-08-28	2001-11-22	Kensey Kenneth R.	In vivo delivery methods and compositions
US6558699B2 (en) *	1997-11-17	2003-05-06	Smithkline Beecham Corporation	High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US20030022928A1 (en) *	1998-03-11	2003-01-30	Smithkline Beecham Corporation	Novel compositions of eprosartan
US20020127254A1 (en) *	1998-06-25	2002-09-12	Lavipharm Laboratories Inc.	Devices for local and systemic delivery of active substance and methods of manufacturing thereof
US6204281B1 (en) *	1998-07-10	2001-03-20	Novartis Ag	Method of treatment and pharmaceutical composition
WO2000027397A1 (en) *	1998-11-06	2000-05-18	Glaxo Group Limited	Antihypertensive medicaments containing lacidipine and telmisartan
PL350924A1 (en) *	1999-04-06	2003-02-10	Sepracor Inc	Derivatives of venlafaxine and methods of preparing and using the same
US6395728B2 (en) *	1999-07-08	2002-05-28	Novartis Ag	Method of treatment and pharmaceutical composition
CA2379666C (en) *	1999-07-21	2009-10-13	Takeda Chemical Industries, Ltd.	Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
DK1216038T3 (da) *	1999-08-30	2005-12-27	Sanofi Aventis Deutschland	Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
US6521647B2 (en) *	2000-04-04	2003-02-18	Pfizer Inc.	Treatment of renal disorders
GB2361185A (en) *	2000-04-10	2001-10-17	Nicholas J Wald	Pharmaceutical formulation for the prevention of cardiovascular disease
TWI246921B (en) *	2000-04-11	2006-01-11	Sankyo Co	Stabilized pharmaceutical composition with calcium blocker
DE10018401A1 (de) *	2000-04-13	2001-10-25	Boehringer Ingelheim Pharma	Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
AU2001284413A1 (en) *	2000-08-30	2002-03-13	Sankyo Company Limited	Medicinal compositions for preventing or treating heart failure
AU2002226365A1 (en) *	2000-12-01	2002-06-11	Novartis Ag	Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
US20030138494A1 (en) *	2001-05-15	2003-07-24	L.A.M. Pharmaceutical Corporation	Drug preparations for treating sexual dysfunction
US20040219208A1 (en) *	2001-08-03	2004-11-04	Ryu Kawamura	Sustained-release medicines
US6680334B2 (en) *	2001-08-28	2004-01-20	Pfizer Inc	Crystalline material
JP2005508358A (ja) *	2001-10-25	2005-03-31	デポメド・インコーポレイテッド	胃滞留型ロサルタン投与量を用いる治療方法
EG24716A (en) *	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
KR20120058618A (ko) *	2003-01-31	2012-06-07	다이이찌 산쿄 가부시키가이샤	동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
HUP0301537A3 (en) *	2003-06-03	2005-07-28	Egis Gyogyszergyar Nyilvanosan	Deramcyclane fumarate tablets and process for producing them
US20040265238A1 (en) *	2003-06-27	2004-12-30	Imtiaz Chaudry	Inhalable formulations for treating pulmonary hypertension and methods of using same
US20050187262A1 (en) *	2004-01-12	2005-08-25	Grogan Donna R.	Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
KR20090102883A (ko) *	2004-09-02	2009-09-30	테바 파마슈티컬 인더스트리즈 리미티드	올메살탄 메독소밀의 정제
JP2006176496A (ja) *	2004-11-24	2006-07-06	Freunt Ind Co Ltd	固形剤およびその製造方法
WO2006059217A1 (en) *	2004-12-01	2006-06-08	Ranbaxy Laboratories Limited	Stable solid dosage forms of amlodipine besylate and processes for their preparation
EP1716139A1 (de) *	2005-01-03	2006-11-02	Teva Pharmaceutical Industries Ltd.	Olmesartan-medoxomil mit reduzierten konzentrationen an verunreinigungen
JP2008538561A (ja) *	2005-04-20	2008-10-30	メルクエンドカムパニーインコーポレーテッド	アンジオテンシンｉｉ受容体アンタゴニスト
TWI407978B (zh) *	2005-06-27	2013-09-11	Sankyo Co	濕粒狀藥物之製備方法
CA2613417C (en) *	2005-06-27	2011-11-29	Daiichi Sankyo Company, Limited	Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
KR20070009851A (ko) *	2005-07-14	2007-01-19	씨제이 주식회사	클로피도그렐 황산수소염 함유 약학 조성물
WO2007031933A2 (en) *	2005-09-12	2007-03-22	Actelion Pharmaceuticals Ltd	Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2007062338A2 (en) *	2005-11-18	2007-05-31	Astrazeneca Ab	Solid formulations
JP2007145646A (ja) *	2005-11-28	2007-06-14	Asahi Glass Co Ltd	プレス成型装置及びプレス成型装置の搬送品搬送方法
ES2279715B1 (es) *	2005-12-26	2008-06-01	Laboratorios Lesvi, S.L.	Formulacion oral de olanzapina.

2007
- 2007-09-14 TW TW096134347A patent/TWI399223B/zh active
- 2007-10-12 WO PCT/GB2007/003933 patent/WO2008032107A1/en not_active Ceased
- 2007-10-12 JP JP2009527899A patent/JP5344620B2/ja active Active
- 2007-10-12 SE SE0900332A patent/SE0900332L/sv unknown
- 2007-10-12 AT AT0939307A patent/AT509493B1/de active
- 2007-10-12 TR TR2009/01984T patent/TR200901984T1/xx unknown
- 2007-10-12 PT PT2007003933A patent/PT2008032107W/pt unknown
- 2007-10-12 BR BRPI0716893-4A2A patent/BRPI0716893A2/pt not_active Application Discontinuation
- 2007-10-12 MY MYPI20091051A patent/MY157716A/en unknown
- 2007-10-12 SK SK5021-2009A patent/SK288460B6/sk unknown
- 2007-10-12 RU RU2009114166/15A patent/RU2423975C2/ru active
- 2007-10-12 NZ NZ575422A patent/NZ575422A/en unknown
- 2007-10-12 AU AU2007297333A patent/AU2007297333B2/en active Active
- 2007-10-12 CH CH00742/08A patent/CH703897B1/de unknown
- 2007-10-12 DE DE212007000063U patent/DE212007000063U1/de not_active Ceased
- 2007-10-12 GB GB0903844A patent/GB2454620B/en active Active
2008
- 2008-12-15 ZA ZA200810616A patent/ZA200810616B/xx unknown
2009
- 2009-03-10 IL IL197518A patent/IL197518A0/en unknown
- 2009-03-11 US US12/401,748 patent/US20090175942A1/en not_active Abandoned
- 2009-03-12 IS IS8808A patent/IS8808A/is unknown
- 2009-03-13 FI FI20090094A patent/FI124122B/fi active IP Right Grant
- 2009-03-16 DK DK200900369A patent/DK200900369A/en not_active Application Discontinuation
2015
- 2015-06-09 US US14/734,893 patent/US20160129008A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ZA200810616B (en)	2009-08-26
US20090175942A1 (en)	2009-07-09
AT509493A5 (de)	2011-09-15
TR200901984T1 (tr)	2009-08-21
IL197518A0 (en)	2009-12-24
WO2008032107A1 (en)	2008-03-20
FI124122B (fi)	2014-03-31
GB0903844D0 (en)	2009-04-22
BRPI0716893A2 (pt)	2014-05-06
CH703897B1 (de)	2012-04-13
TW200817052A (en)	2008-04-16
FI20090094L (fi)	2009-03-13
DK200900369A (en)	2009-03-16
JP5344620B2 (ja)	2013-11-20
TWI399223B (zh)	2013-06-21
GB2454620A (en)	2009-05-13
SK50212009A3 (sk)	2009-06-05
AU2007297333A1 (en)	2008-03-20
HK1127282A1 (en)	2009-09-25
IS8808A (is)	2009-03-12
DE212007000063U1 (de)	2009-05-14
AT509493B1 (de)	2012-01-15
SK288460B6 (sk)	2017-03-01
US20160129008A1 (en)	2016-05-12
SE0900332L (sv)	2009-06-12
PT2008032107W (pt)	2013-07-09
NZ575422A (en)	2011-01-28
AU2007297333B2 (en)	2010-10-28
GB2454620B (en)	2011-08-17
RU2423975C2 (ru)	2011-07-20
RU2009114166A (ru)	2010-10-20
JP2011500505A (ja)	2011-01-06

Publication	Publication Date	Title
MY157716A (en)	2016-07-15	Solid dosage form of olmesartan medoxomil and amlodipine
IL181549A0 (en)	2007-07-04	Preparation of olmesartan medoxomil
ZA200810053B (en)	2009-11-25	Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
SI2428513T1 (sl)	2017-10-30	Derivati 5-substituiranega kinazolinona kot sredstva proti-raku
IL199397A (en)	2014-07-31	Hetero-ring compounds, pharmaceuticals containing them, and their medicinal products
IL193467A0 (en)	2009-09-22	Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
EP2070075A4 (de)	2012-04-04	Nachrichtenübermittlung einschliesslich eines aktivantwortmerkmals
MY144857A (en)	2011-11-30	Phamaceutical composition comprising amlodipine and losartan
ZA200809941B (en)	2009-07-29	2-anilino-4-(heterocyclic)amino-pyrimidines
ZA200810640B (en)	2010-01-27	1,5 -Diphenylpyrazoles II as HSP90 Inhibitors
IL183233A0 (en)	2007-08-19	Olmesartan medoxomil with reduced levels of impurities
MY147263A (en)	2012-11-30	Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists
IL217500A0 (en)	2012-02-29	Tetrazole derivatives, their preparartion and pharmaceutical compositions containing them
BRPI0720314A2 (pt)	2013-12-24	Composição, e, usos de uma composição e de um composto de triazol.
GB0616794D0 (en)	2006-10-04	Solid dosage form
TW200833359A (en)	2008-08-16	Elution-improved pharmaceutical preparation
WO2008078729A1 (ja)	2008-07-03	溶出性改善方法
WO2006106358A3 (en)	2006-12-28	Use of nk-3 receptor antagonists for the treatment of nausea and vomiting
WO2008028885A3 (en)	2008-05-02	Composition comprising an angiotensin ii receptor antagonist
TW200833325A (en)	2008-08-16	Pharmaceutical composition comprising ascorbic acid
HK1127282B (en)	2012-02-10	Solid dosage form of olmesartan medoxomil and amlodipine
MX2009006313A (es)	2009-06-23	Antagonistas v3 para el tratamiento o prevencion de dolor cronico.
PL388087A1 (pl)	2009-12-07	Forma stała medoksomilu olmesartanu i amlodypiny
HU0600502D0 (en)	2006-08-28	Active ingredient against candida
HK1128001A (en)	2009-10-16	Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same